A bill was proposed to amend the law and improve patient access to Novartis’s Kymirah, the ultra-high-priced ‘one-shot drug,’ by realistically amending the requirements for institutions that use the drug.

The main point of the amendment is to allow hematopoietic stem cell transplant institutions designated as transplant hospitals to provide Kymriah treatment.

Rep. Young Woo Lee of the Democratic Party of Korea proposed the bill for the ‘Partial Amendment to the Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products’ that contained the proposal above on the 27th.

Kymriah was approved in March 2021 as the world’s first chim